- Call us : +91 9997771321
- Email : [email protected]
EndoPredict
The EndoPredict test is a genetic test for persons who have just been diagnosed with estrogen-receptor-positive, HER2-negative breast cancer in the early stages. The EndoPredict test, according to research, might be extensively used to aid treatment decisions based on cancer’s chance of recurrence in a portion of the body other than the breast within 10 years of diagnosis. The EndoPredict test determines if a breast cancer recurrence as distant metastasis is low-risk or high-risk. Knowing whether cancer has a high or low chance of recurrence might help women and their doctors decide whether chemotherapy or other risk-reducing treatments are needed after surgery.
What are genomic tests?
A sample of a malignant tumor is analyzed using genomic assays to determine how active specific genes are. The level of activity of these genes influences cancer’s behavior, including how likely it is to develop and spread. Genomic tests are performed to assist determine whether additional treatments following surgery are necessary. Despite their similar names, genomic testing and genetic testing are not the same.
A sample of your blood, saliva, or other tissue is tested to see if you have an aberrant change (also known as a mutation) in a gene related to an increased risk of breast cancer. For further information, go to the Genetic Testing website.
Who is eligible for the EndoPredict test?
If you’ve just been diagnosed with stage I or II estrogen receptor-positive, HER2-negative breast cancer with no cancer in your lymph nodes (node-negative disease) OR cancer in one to three lymph nodes, you might be a candidate for the EndoPredict test. You and your doctor are debating whether or not to undergo chemotherapy.
The EndoPredict test may help you and your doctor make a better educated decision about chemotherapy following surgery if you’ve been diagnosed with early-stage, estrogen-receptor-positive, and HER2-negative breast cancer.